In the SOCOGAMI study and the EMBODY trial, the effect of SGLT2 inhibitors on cardiometabolic parameters in patients without a diagnosis of heart failure was evaluated, and it was found that SGLT2 inhibitors had no significant effect on BNP levels in these patients [35,36]. This evidence concerns the gene SLC5A2 and heart failure.